Agents, uses and methods for the treatment of synucleinopathy

Patent metadata

Field	Value
Publication number	US-11421024-B2
Application number	US-202017004447-A
Country	US
Kind code	B2
Filing date	Aug 27, 2020
Priority date	Jul 13, 2015
Publication date	Aug 23, 2022
Grant date	Aug 23, 2022

Abstract

The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy.

First claim

The invention claimed is:

1. An isolated nucleic acid encoding an antibody which specifically binds to human alpha-synuclein, wherein the antibody comprises:
(a) heavy chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 20, 21, and 22, respectively, and light chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 23, 24, and 25, respectively;
(b) heavy chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively, and light chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 4, 5, and 6, respectively;
(c) heavy chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 1, 33, and 3, respectively, and light chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 4, 5, and 6, respectively;
(d) heavy chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 1, 34, and 3, respectively, and light chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 4, 5, and 6, respectively; or
(e) heavy chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 1, 35, and 3, respectively, and light chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 4, 5, and 6, respectively.

2. The nucleic acid of claim 1 , wherein the antibody comprises:
(a) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 26 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 27;
(b) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 8;
(c) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 30 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 8;
(d) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 31 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 8; or
(e) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 32 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 8.

3. The nucleic acid of claim 1 , wherein the antibody is a single chain Fv, a disulphide-bonded Fv, an Fab fragment, a Fab′ fragment, or a F(ab) 2 fragment.

4. The nucleic acid of claim 1 , wherein the antibody is a human antibody.

5. An expression vector comprising the nucleic acid of claim 1 .

6. A host cell comprising the expression vector of claim 5 .

7. A host cell comprising the nucleic acid of claim 1 .

8. The host cell of claim 7 , which is a mammalian cell.

9. The host cell of claim 8 , which is a CHO cell or HEK cell.

10. A method of producing an antibody which binds to alpha-synuclein, the method comprising culturing the host cell of claim 7 under conditions suitable for producing the antibody in a culture medium, and optionally isolating the antibody from the culture medium.

11. A composition comprising a first isolated nucleic acid encoding a heavy chain of an antibody and a second isolated nucleic acid encoding a light chain of an antibody, wherein:
(a) the heavy chain comprises heavy chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 20, 21, and 22, respectively, and the light chain comprises and light chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 23, 24, and 25, respectively;
(b) the heavy chain comprises heavy chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively, and the light chain comprises light chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 4, 5, and 6, respectively;
(c) the heavy chain comprises heavy chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 1, 33, and 3, respectively, and the light chain comprises light chain CDR1, CDR2, and CDR3 comprising the aminoacid sequences of SEQ ID NOs: 4, 5, and 6, respectively;
(d) the heavy chain comprises heavy chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 1, 34, and 3, respectively, and the light chain comprises light chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 4, 5, and 6, respectively; or
(e) the heavy chain comprises heavy chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 1, 35, and 3, respectively, and the light chain comprises light chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 4, 5, and 6, respectively.

12. The composition of claim 11 , wherein:
(a) the heavy chain comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 26 and the light chain comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 27;
(b) the heavy chain comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 7 and the light chain comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 8;
(c) the heavy chain comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 30 and the light chain comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 8;
(d) the heavy chain comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 31 and the light chain comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 8; or
(e) the heavy chain comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 32 and the light chain compromises a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 8.

13. The composition of claim 11 , wherein the antibody is a single chain Fv, a disulphide-bonded Fv, an Fab fragment, a Fab′ fragment, or a F(ab) 2 fragment.

14. The composition of claim 11 , wherein the antibody is a human antibody.

15. A composition comprising a first expression vector and a second expression vector, wherein the first and second expression vectors comprise the first and second isolated nucleic acids of claim 11 , respectively.

16. A host cell comprising the first and second expression vectors of claim 15 .

17. A host cell comprising the first and second isolated nucleic acids claim 11 .

18. The host cell of claim 17 , which is a mammalian cell.

19. The host cell of claim 18 , which is a CHO cell or HEK cell.

20. A method of producing an antibody which binds to alpha-synuclein, the method comprising culturing a host cell comprising a nucleic acid encoding a heavy chain of the antibody and a separate nucleic acid encoding a light chain of the antibody under conditions suitable for producing the antibody in a culture medium, and optionally isolating the antibody from the culture medium, wherein the antibody comprises:
(a) heavy chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 20, 21, and 22, respectively, and light chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 23, 24, and 25, respectively;
(b) heavy chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively, and light chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 4, 5, and 6, respectively;
(c) heavy chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 1, 33, and 3

Assignees

• H Lundbeck As

Inventors

• Kallunki Pekka
• Fog Karina
• Vesterager Louise Buur
• Bergstrôm Ann-Louise
• Sotty Florence
• Satijn David
• Van Den Brink Edward
• Parren Paul
• Rademaker Rik
• Vink Tom
• Malik Ibrahim John
• Montezinho Liliana Christina Pereira

Classifications

• A61K39/395 Primary

  Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61P25/16

  Anti-Parkinson drugs · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• G01N2800/2835

  Movement disorders, e.g. Parkinson, Huntington, Tourette · CPC title